Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Antiphospholipid syndrome (APS) is an autoimmune thrombo‐inflammatory disorder characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS manifestations, including microvascular injury and diffuse

Click on the article title to read more.

ObjectivesSystemic lupus erythematosus (SLE) is an autoimmune disease in which rare and common gene variants contribute to pathogenesis. Severe sporadic disease in children is often explained by ‘de novo’ variants that can be uncovered by trio sequencing.MethodsWhole exome sequencing was performed in 50 Chinese trios with childhood‐onset SLE (cSLE). Rare coding variants in SLE‐associated genes and

ObjectiveTo investigate the role of senescent epidermal basal cells in cutaneous lupus erythematosus (CLE) pathogenesis using skin samples from patients with CLE and a mouse model of systemic lupus erythematosus (SLE).MethodsCellular senescence profiling utilized datasets from the NCBI Gene Expression Omnibus database and Accelerating Medicines Partnership® (AMP®) Phase 1‐Metro. Gene array data from

ObjectiveRaynaud's phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts.MethodsAll patient data in the GENISOS and

ObjectiveThis study quantifies the global burden of osteoarthritis (OA) attributable to high body mass index (BMI) from 1990 to 2021 using the Global Burden of Disease (GBD) 2021 data.MethodsUtilizing GBD 2021 data, this research examines the OA burden related to high BMI across 204 countries and regions. Statistical analyses were performed to profile disease burdens, and joinpoint regression was used

Click on the article title to read more.

Click on the article title to read more.

ObjectivesTo reveal causal level osteoarthritis (OA) disease biology by targeting regulatory interactions at GDF5.MethodsBy investigating different GDF5 regulatory regions (R2, R3‐5, R7‐R9, R18‐20, GROW1) we explored their functional impacts on gene expression and joint morphology in vivo and in vitro. We additionally modeled OA variants in said enhancers in vitro and in vivo mouse models for expression

ObjectivesGenome wide association studies (GWAS) have identified >100 loci for systemic lupus erythematosus (SLE). These loci may also impact age of diagnosis. We aimed to identify genetic variants for age of SLE diagnosis, and to complete a GWAS of childhood‐onset SLE (cSLE) diagnosed <18 years of age.MethodsPatients met ACR and/or SLICC SLE classification criteria, had documented age at diagnosis

Click on the article title to read more.

Click on the article title to read more.

ObjectiveThe presence of anti‐nuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti‐dsDNA is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated with disease activity. Antibody dynamics of other

Click on the article title to read more.

ObjectivesSystemic juvenile idiopathic arthritis (sJIA) is a chronic childhood disease classically attributed to innate immune cell dysregulation. This study aimed to elucidate the role of innate lymphoid cells (ILCs), including natural killer (NK) cells and helper‐ILCs (hILCs), in sJIA during clinically inactive disease (CID) through phenotypic and functional analysis.MethodsPeripheral ILCs from children

Click on the article title to read more.

To assess the impact of differences in the timing of initial biologic DMARD (bDMARD) therapy using the CARRA STOP-JIA polyarticular JIA (pJIA) consensus treatment plans (CTPs) study on outcomes through 3 years.

ObjectiveTo develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR).MethodsThis international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3)

ObjectiveThe field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but a validated risk stratification method is lacking. This work was undertaken to develop a risk stratification method for persons presenting with arthralgia considered to be at risk of RA.MethodsA joint EULAR/American College of Rheumatology (ACR) expert committee was established

Click on the article title to read more.

ObjectiveThe SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks.This study aimed to assess relapse rates after stopping TCZ in patients achieving remission at week 24.MethodsIn the randomized study, 101 patients received intravenous TCZ (8 mg/kg) or placebo for 24 weeks

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

‐

ObjectiveThe objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.MethodsThe Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading

Click on the article title to read more.

ObjectiveThis study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials.MethodsPatients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose glucocorticoids. Patients had baseline kidney biopsies within

Click on the article title to read more.

Click on the article title to read more.

Ji A, Sui Y, Xuo X, et al. Novel Genetic Loci in Early-Onset Gout Derived From Whole-Genome Sequencing of an Adolescent Gout Cohort. Arthritis Rheumatol. 2025 Jan;77(1):107–115. In the article noted above, the author name Xiapeng Ji is misspelled. The correct spelling is Xiaopeng Ji. We apologize for this error.

BackgroundPodocytes are integral to the maintenance of the glomerular filtration barrier. Their injury results in proteinuria and disease progression in lupus nephritis (LN). Aberrant IgG glycosylation drives podocyte injury in LN and leads to cytoskeletal rearrangement, motility changes and decreased nephrin production. Based on these findings, we hypothesized that IgG glycosylation patterns differentiate

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

To assess the relationship of circulating and synovial immune cells with synovial molecular pathology and disease outcomes in early Rheumatoid Arthritis (RA).

Arthritis Rheumatol. 2023 Jul;75(7):1187-1202. doi: 10.1002/art.42462. Epub 2023 Apr 19. In Figure 3A, the labels for the two WT TACI-Fc comparators on the y-axis were inverted. The 2nd bar from the top should have been labeled “WT TACI 30-110 Ig” and the 3rd bar from the top should have been labeled “WT TACI 13-118 Ig.” We apologize for this error.

Click on the article title to read more.

Click on the article title to read more.

ObjectivesTapering of tumor necrosis factor inhibitor (TNFi) treatment in rheumatoid arthritis (RA) remission is debated. We assessed the effect of tapering TNFi to withdrawal versus continued stable TNFi on flare‐free survival and joint damage progression over three years.MethodsARCTIC REWIND was a multicenter, open‐label, non‐inferiority trial including patients with RA in remission for ≥12 months

Click on the article title to read more.

Click on the article title to read more.

ObjectivePatients with primary Sjögren Disease (pSD) are prone to develop non‐Hodgkin's lymphoma (NHL‐pSD) but relevant biomarkers are lacking. We aimed to determine new biomarkers predictive of NHL in patients with pSD.Methods206 pSD patients fulfilling ACR/EULAR 2016 criteria were included and divided into three groups: pSD, lymphoproliferative pSD (Arl‐pSD), and NHL‐pSD. Deep flow cytometry immunophenotyping

Click on the article title to read more.

Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy. Myeloid and lymphoid hematologic malignancy have long been recognized in

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

ObjectiveTo assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.MethodsRA patients from 15 registries in the JAK‐pot collaboration were included. MACE incidence was analysed using two approaches: a